



# UNDERSTANDING THE ROLE OF *BRAF* MUTATIONS IN METASTATIC MELANOMA

Melanoma is a form of skin cancer that develops when unrepaired DNA damage to skin cells triggers mutations that may lead them to **multiply and form “malignant,” or cancer-causing, tumors.**<sup>1</sup>




**Metastatic melanoma is the most serious and life-threatening type of skin cancer and is associated with low survival rates.**<sup>3,4</sup>

## *BRAF*-Mutant Metastatic Melanoma



### *BRAF*

A variety of genetic mutations can lead to metastatic melanoma, but the most common is *BRAF*.<sup>1,5</sup>



### ~50%

of metastatic melanoma cases have the *BRAF* GENE MUTATION, a key target in the treatment of metastatic melanoma.<sup>5</sup>

## Role of *BRAF* and the MAPK Signaling Pathway

The majority of melanomas have mutations associated with the mitogen-activated protein kinase (MAPK) pathway, which is involved in cancer cell growth, differentiation and survival.<sup>5</sup>



*BRAF* and MEK are key protein kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Clinicians target this pathway to treat advanced melanoma.<sup>6</sup>



Targeted therapy with *BRAF* and MEK inhibitors has evolved to become a standard of care for patients with advanced or metastatic *BRAF*-mutant melanoma.<sup>7</sup>

**ARRAY**  
BIOPHARMA

[1] American Cancer Society. What Causes Melanoma Skin Cancer? 2016. <https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-prevention/what-causes.html>.

[2] American Cancer Society. Cancer Facts & Figures 2018. Atlanta, GA: American Cancer Society; 2018. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf>

[3] National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Melanoma of the Skin. Bethesda, MD: National Cancer Institute. <https://seer.cancer.gov/statfacts/html/melan.html>.

[4] American Cancer Society. Survival Rates for Melanoma Skin Cancer, by Stage. 2016. <https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html>.

[5] Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for *BRAF* mutations to inform melanoma treatment decisions: a move toward precision medicine. *Mod Pathol*. 2018;31(1):24-38.

[6] Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. *IUBMB Life*. 2013;65(9):748-758.

[7] Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol*. 2017;14(8):463-482.